Navigation Links
Intensified chemotherapy shows promise for children with very high risk form of leukemia
Date:12/10/2012

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.

The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute lymphoblastic leukemia (B-ALL), at the annual meeting of the American Society of Hematology (ASH) conference.

Trial participants received an initial course of "induction" chemotherapy for B-ALL, a cancer of the blood that is one of the most common cancers in children below age 15. After a month of treatment, the patients had a bone marrow sample sent for a test able to measure levels of leukemia that cannot be seen under a microscope.

Thirty-five of the patients were deemed to have a very high risk of relapsing because they retained relatively large numbers of leukemia cells as measured by this test. An additional 16 patients were also considered very high-risk because their leukemia cells had certain chromosomal abnormalities.

These 51 patients then received an intensified treatment regimen consisting of two additional rounds of chemotherapy using agents not typically given to newly diagnosed patients with B-ALL. This was followed by an intensified consolidation phase of therapy to keep the disease in remission, and then a standard maintenance phase to further deter the disease from returning.

Investigators estimate that, five years after reaching complete remission, the rate of event-free survival (a measure of survival without relapse or development of another cancer) was 76 percent for these very high-risk patients. By contrast, less than half of similar patients who receive standard chemotherapy reach the five-year mark without relapsing.

"Pediatric patients with B-ALL traditionally receive a standard course of chemotherapy if their risk of relapse is low, and a slightly intensified course if their risk is higher," says the study's lead author, Lynda Vrooman, MD, of Dana-Farber/Children's Hospital Cancer Center. "In this study, we identified a new risk group those with a very high risk of relapse and studied the effect of a novel, even more intensive chemotherapy regimen on their outcome."

"Though it involved a relatively small number of patients, the new trial is one of the first to show improved outcomes for this set of patients as a result of an intensified chemotherapy protocol," says senior author Lewis Silverman, MD, of Dana-Farber/Children's Hospital Cancer Center. Trial leaders will continue to track the study participants to gauge the durability of the remissions produced by the intensified treatment.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. UCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy
2. Immune system kill switch could be target for chemotherapy and infection recovery
3. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
4. Improving chemotherapy effectiveness by acting on the immune system
5. Nanomedicine breakthrough could improve chemotherapy for childhood cancer
6. Researchers develop non-invasive technique for predicting patients response to chemotherapy
7. Recent findings may help to fight melanomas resistance to chemotherapy
8. Key discovered to how chemotherapy drug causes heart failure
9. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
10. UCI researchers find cause of chemotherapy resistance in melanoma
11. Weizmann Institutes mathematical model may lead to safer chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017   Divoti ... Medical Alert Jewelry up to the standard of the latest FDA ... (Launched: June 2017). Anyone in need of Medical ID ... Divoti Medical Alert Jewelry are engraved in terms of the ... ...
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: